First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.

导出原文传递

翻译打印收藏纠错

第一作者： Chang Gon,Kim

第一单位： Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

作者： Chang Gon,Kim ^[1] ; Miso,Kim ^[2] ; Jieon,Hwang ^[3] ; Seung Tae,Kim ^[4] ; Minkyu,Jung ^[1] ; Kyoo Hyun,Kim ^[1] ; Kyung Hwan,Kim ^[5] ; Jee Suk,Chang ^[5] ; Woong Sub,Koom ^[5] ; Mi Ryung,Roh ^[6] ; Kee Yang,Chung ^[7] ; Tae Min,Kim ^[2] ; Sang Kyum,Kim ^[8] ; Jeeyun,Lee ^[9] ; Sang Joon,Shin ^[10]

作者单位： Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[1] Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. ^[2] Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[3] Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ^[4] Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[5] Department of Dermatology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[6] Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. ^[7] Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: nicekyumi@yuhs.ac. ^[8] Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: jyunlee@skku.edu. ^[9] Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: ssj338@yuhs.ac. ^[10]

关键词 BRAF V600–mutant advanced melanoma dabrafenib/trametinib first-line treatment pembrolizumab